Literature DB >> 28283701

Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging.

Paolo Zanotti-Fregonara1, Clément Morgat2, Christophe Champion3, Elif Hindié2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28283701     DOI： 10.1007/s00259-017-3667-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  10 in total

1.  Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT).

Authors:  Michael S Hofman; Michael Michael; Raghava Kashyap; Rodney J Hicks
Journal:  J Nucl Med       Date:  2015-03-26       Impact factor: 10.057

2.  Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.

Authors:  Phillip G Claringbold; J Harvey Turner
Journal:  Neuroendocrinology       Date:  2015-06-10       Impact factor: 4.914

3.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245

4.  SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.

Authors:  C Kratochwil; M Stefanova; E Mavriopoulou; T Holland-Letz; A Dimitrakopoulou-Strauss; A Afshar-Oromieh; W Mier; U Haberkorn; F L Giesel
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

5.  Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.

Authors:  Maddalena Sansovini; Stefano Severi; Annarita Ianniello; Silvia Nicolini; Lorenzo Fantini; Emilio Mezzenga; Fabio Ferroni; Emanuela Scarpi; Manuela Monti; Alberto Bongiovanni; Sara Cingarlini; Chiara Maria Grana; Lisa Bodei; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-04       Impact factor: 9.236

6.  Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.

Authors:  Ezgi Ilan; Mattias Sandström; Cecilia Wassberg; Anders Sundin; Ulrike Garske-Román; Barbro Eriksson; Dan Granberg; Mark Lubberink
Journal:  J Nucl Med       Date:  2015-01-15       Impact factor: 10.057

7.  Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.

Authors:  Camilla B Johnbeck; Ulrich Knigge; Seppo W Langer; Annika Loft; Anne Kiil Berthelsen; Birgitte Federspiel; Tina Binderup; Andreas Kjaer
Journal:  J Nucl Med       Date:  2016-07-28       Impact factor: 10.057

8.  High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.

Authors:  Haïfa Bahri; Lenoir Laurence; Julien Edeline; Houda Leghzali; Anne Devillers; Jean-Luc Raoul; Marc Cuggia; Habiba Mesbah; Bruno Clement; Eveline Boucher; Etienne Garin
Journal:  J Nucl Med       Date:  2014-10-06       Impact factor: 10.057

9.  18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.

Authors:  Tina Binderup; Ulrich Knigge; Annika Loft; Birgitte Federspiel; Andreas Kjaer
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

10.  Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.

Authors:  Bernhard Nilica; Dietmar Waitz; Vlado Stevanovic; Christian Uprimny; Dorota Kendler; Sabine Buxbaum; Boris Warwitz; Llanos Gerardo; Benjamin Henninger; Irene Virgolini; Margarida Rodrigues
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-27       Impact factor: 9.236
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.